Looking to buy Macquarie shares? The bank is 'positioned for an earnings recovery': fundie

2024 is shaping up to be Macquarie's year, according to this expert.

Key points
  • The Macquaire share price has suffered through 2022, falling 15% year to date
  • Meanwhile, the company posted a $2.3 billion profit for the first half of financial year 2023
  • One fundie thinks there might be short term pain in store for the company, but believes 2024 could bring an 'earnings recovery' 

Those interested in snapping up Macquarie Group Ltd (ASX: MQG) shares have likely poured over the company's recent half year earnings.

It posted a $2.3 billion profit for the six months ended 30 September. The investment banking giant also lifted its interim dividend 10% to $3 per share.

The market responded well to the earnings. It bid the Macquarie share price 1.8% higher on the release and it has gained another 5.8% since. The Macquarie share price closed Friday's trade at $179.32.

However, that's 15% lower than it was at the start of 2022 and 13% lower than it was this time last year. For comparison, the S&P/ASX 200 Index (ASX: XJO) has slipped 6% year to date and 3% over the last 12 months.

But one broker sees hope in the bank stock, tipping it as a buy and predicting its earnings to pick up in the coming years. Here's why Baker Young managing portfolio analyst Toby Grimm is bullish on the ASX 200 giant.

A group of businesspeople clapping.

Image source: Getty Images

What could the future bring for Macquarie shares?

Grimm believes now is a good time to buy shares in ASX 200 investment banking giant Macquarie.

The fundie said, as per The Bull, "the company's diversified business model is appealing". But there might be some short-term pain in store for the stock.

Grimm pointed out that, while Macquarie's first half profit was a 13% increase on that of the prior corresponding period, it also marked a 13% drop on that of the second half of financial year 2022, which came in at around $2.66 billion.

As a result, the fundie thinks the ASX 200 giant's "full year will be tough", but the future is brighter. Grimm continues:

[B]ut we believe the investment bank is positioned for an earnings recovery in 2024.

Grimm isn't alone in liking the investment bank. Morgans tips it as a buy, with a price target of $214.30. Meanwhile, Goldman Sachs is neutral on the stock, expecting it to rise to $188.35.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Couple using their digital tablet together.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Young successful engineer, with blueprints, notepad, and digital tablet, observing the project implementation on construction site and in mine.
Broker Notes

Why the Paladin Energy share price "doesn't make sense"

This uranium stock could be set for a major re-rating.

Read more »

Two miners standing together.
Broker Notes

3 ASX 200 mining shares to buy with 41% to 79% upside ahead: broker

The green energy transition and other factors are providing strong growth drivers for mining.

Read more »

Happy miner with his arms folded.
Broker Notes

Buy, hold, sell: Paladin Energy, Fortescue, Rio Tinto shares

Let's take a look at some new ratings from Morgans.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

9 ASX 200 shares experts are backing for growth amid market weakness

Brokers retained a positive view on BHP, CSL, Telstra, Xero, and other shares this week. 

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

This ASX biotech could rise 40% or 750%, depending on who you ask

A poor quarter has reduced expectations, but there's still plenty of upside.

Read more »

Man using his device in an airport.
Broker Notes

This high-quality ASX 200 share could rise 60%

A leading broker expects a good yield and major upside from this stock.

Read more »

A baby's eyes open wide in surprise as it sucks on a milk bottle.
Broker Notes

Trading near 12-month lows, this ASX retailer could be set for a 54% gain

This baby goods retailer still has ample room to grow.

Read more »